Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

INDUSTRY 3 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4 Breast Neoplasms 4 Triple Negative Breast Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Head and Neck Neoplasms 2 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Sarcoma 1 Rectal Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Muscle Invasive Bladder Cancer (MIBC) 1 Hemangiosarcoma 1 Endometrial Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1

Interventions

Gemcitabine 58 Cisplatin 41 Capecitabine 27 Oxaliplatin 25 durvalumab 16 Fluorouracil 16 Leucovorin 15 S 1 (combination) 11 lenvatinib 10 Nivolumab 10 Irinotecan 10 pembrolizumab 8 apatinib 8 Immune Checkpoint Inhibitors 7 130-nm albumin-bound paclitaxel 7 tremelimumab 6 Bevacizumab 6 camrelizumab 5 Trastuzumab 5 Drug Therapy 5 Blood Specimen Collection 5 Albumin-Bound Paclitaxel 5 tislelizumab 4 irinotecan sucrosofate 4 Taxes 4 Liquid Biopsy 4 Folfox protocol 4 toripalimab 3 surufatinib 3 gemcitabine-oxaliplatin regimen 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Biliary Tract Neoplasms × zanidatamab × Clear all

NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡